← Back to All Filings
Vertex Pharmaceuticals Director Alan Garber Receives Routine Deferred Stock Units
VERTEX PHARMACEUTICALS INC / MA
$VRTX4CIK: 0000875320
Subscribe to track VRTX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
{
"embeds": [{
"title": "Vertex Pharmaceuticals Inc ($VRTX) - Insider Award",
"color": 3447003,
"fields": [
{"name": "Insider", "value": "Alan M. Garber (Director)", "inline": true},
{"name": "Transaction Type", "value": "Grant (Deferred Stock Units)", "inline": true},
{"name": "Amount", "value": "29.272 units @ $512.44 (~$15.0K)", "inline": false},
{"name": "Post-Transaction Holdings", "value": "94.73 units", "inline": true}
],
"footer": {"text": "SEC Form 4 • Filed Oct 19, 2026"}
}]
}
Comprehensive Analysis
Insider Transaction Analysis: Vertex Pharmaceuticals Inc (NASDAQ: VRTX)
Overview
On October 15, 2026, Director Alan M. Garber acquired 29.272 Deferred Stock Units (DSUs) of Vertex Pharmaceuticals Inc at a stated price of $512.44 per share, corresponding to an aggregate value of $15,000.14.
Key Details
- Transaction Code:
A(Award/Grant). - Nature of Security: Deferred Stock Units, each representing the right to receive one share of common stock upon cessation of board service, a change in control, or death/disability.
- Ownership Post-Transaction: Dr. Garber now holds 94.73 DSUs directly following this acquisition.
Market Significance
- Trading Significance: Low.
- This transaction represents a routine equity grant or director fee deferral common in corporate governance compensation structures, rather than an open-market purchase or sale. It does not reflect discretionary market sentiment.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.